Extended pelvic lymph node dissection in prostate cancer: A 20-year audit in a single center

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1459-1466

  Abdollah, F ^a   Suardi, N ^a   Gallina, A ^a   Bianchi, M ^a   Tutolo, M ^a   Passoni, N ^a   Fossati, N ^a   Sun, M ^b   dell'Oglio, P ^a   Salonia, A ^a   Karakiewicz, P I ^b   Rigatti, P ^a   Montorsi, F ^a   Briganti, A ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Extended pelvic lymph node dissection; Lymph node invasion; Prostate cancer; Risk groups; Stage migration

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE CLASSIFICATION; EXTENDED PELVIC LYMPH NODE DISSECTION; GLEASON SCORE; HUMAN; HUMAN TISSUE; LYMPH NODE; LYMPH NODE DISSECTION; LYMPH NODE INVASION; LYMPHOCELE; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; POSTOPERATIVE EDEMA; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SURGERY; PROSTATECTOMY; TREND STUDY;

EID: 84878459792     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt120     Document Type: Article

References (24)

1. Cooperberg MR, Lubeck DP, Mehta SS et al. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003; 170: S21-S25; discussion S26-S27.
2. Gallina A, Chun FK, Suardi N et al. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int 2008; 101: 1513-1518.
3. Abdollah F, Sun M, Thuret R et al. Decreasing rate and extent of lymph node staging in patients undergoing radical prostatectomy may undermine the rate of diagnosis of lymph node metastases in prostate cancer. Eur Urol 2010; 58: 882-892.
4. Galper SL, Chen MH, Catalona WJ et al. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol 2006; 175: 907-912.
5. Feifer AH, Elkin EB, Lowrance WT et al. Temporal trends and predictors of pelvic lymph node dissection in open or minimally invasive radical prostatectomy. Cancer 2011; 117: 3933-3942.
6. Kawakami J, Meng MV, Sadetsky N et al. Changing patterns of pelvic lymphadenectomy for prostate cancer: results from CaPSURE. J Urol 2006; 176: 1382-1386.
7. Abdollah F, Sun M, Thuret R et al. Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer. Int J Urol 2012; 19: 645-651.
8. Briganti A, Chun FK, Salonia A et al. Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy. Urology 2007; 69: 147-151.
9. Godoy G, von Bodman C, Chade DC et al. Pelvic lymph node dissection for prostate cancer: frequency and distribution of nodal metastases in a contemporary radical prostatectomy series. J Urol 2012; 187: 2082-2086.
10. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002; 167: 1681-1686.
11. Touijer K, Fuenzalida RP, Rabbani F et al. Extending the indications and anatomical limits of pelvic lymph node dissection for prostate cancer: improved staging or increased morbidity? BJU Int 2011; 108: 372-377.
12. Bochner BH, Cho D, Herr HW et al. Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping. J Urol 2004; 172: 1286-1290.
13. Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 2007; 51: 1175-1184.
14. Dorin RP, Daneshmand S, Lassoff MA et al. Long-term outcomes of open radical retropubic prostatectomy for clinically localized prostate cancer in the prostatespecific antigen era. Urology 2012; 79: 626-631.
15. Eggener SE, Scardino PT, Walsh PC et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185: 869-875.
16. Budaus L, Spethmann J, Isbarn H et al. Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade. BJU Int 2011; 108: 1256-1261.
17. Cooperberg MR, Cowan J, Broering JM et al. High-risk prostate cancer in the United States, 1990-2007. World J Urol 2008; 26: 211-218.
18. Ploussard G, Masson-Lecomte A, Beauval JB et al. Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification. Urology 2011; 78: 607-613.
19. Walz J, Joniau S, Chun FK et al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int 2011; 107: 765-770.
20. Briganti A, Karnes RJ, Da Pozzo LF et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol 2011; 59: 832-840.
21. Messing EM, Manola J, Yao J et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-479.
22. Capitanio U, Pellucchi F, Gallina A et al. How can we predict lymphorrhoea and clinically significant lymphocoeles after radical prostatectomy and pelvic lymphadenectomy? Clinical implications. BJU Int 2011; 107: 1095-1101.
23. Clark T, Parekh DJ, Cookson MS et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 2003; 169: 145-147; discussion 147-148.
24. Albertsen PC, Hanley JA, Barrows GH et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005; 97: 1248-1253.